EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The evolving diagnosis and treatment paradigms of multiple myeloma in China: 15 years' experience of 1256 patients in a national medical center

Yang Yang, Jing Li, Wenjing Wang, Yawen Wang, Aziguli Maihemaiti, Liang Ren, Tianwei Lan, Chi Zhou, Panpan Li iD, Pu Wang, Xianmuseye Aihemaiti, Feifei Chen und 3 weitere

Cancer Medicine · 2023

DOI: 10.1002/cam4.5737 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Yang Yang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Multiple Myeloma, Amyloidosis. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Shanghai.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Significant advances in multiple myeloma (MM) over the past 15 years led to exciting changes in the management of MM patients in China, which in turn brought about the early diagnoses, precise risk stratifications, and improved prognoses.

Methods

We summarized the dynamic changes in the management of newly diagnosed (ND) MM in a national medical center, crossing the old and novel drug era. Demographics, clinical characteristics, first‐line treatment, response rate, and survival were retrospectively collected among NDMMs diagnosed in Zhongshan Hospital Fudan University from January 2007 to October 2021.

Results

Of the 1256 individuals, median age was 64 (range 31–89) with 45.1% patients >65 years. About 63.5% were male, 43.1% were at ISS stage III and 9.9% had light‐chain amyloidosis. Patients with abnormal ratio of free light chain (80.4%), extramedullary disease (EMD, 22.0%), and high‐risk cytogenetic abnormalities (HRCA, 26.8%) were detected by novel detection techniques. The best confirmed ORR was 86.5%, including 39.4% with CR. Short‐ and long‐term PFS and OS rates persistently increased each year along with increasing novel drug applications. Median PFS and OS were 30.9 and 64.7 months. Advanced ISS stage, HRCA, light‐chain amyloidosis and EMD independently predicted an inferior PFS. First‐line ASCT indicated a superior PFS. Advanced ISS stage, elevated serum LDH, HRCA, light‐chain amyloidosis, and receiving PI/IMiD‐based regimen versus PI+IMiD‐based regimen independently indicated a poorer OS.

Conclusions

In brief, we illustrated a dynamic landscape of MM patients in a national medical center. Chinese MM patients evidently benefited from newly introduced techniques and drugs in this field.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaAmyloidosisHumansMaleAdultMiddle AgedAgedAged, 80 and overFemaleRetrospective StudiesPrognosisHospitals

Stichwörter der Autor:innen

clinical observationscytogeneticsmultiple myelomaprognosis

Autor:innen und Institutionen

  • Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China.

ORCID-Profile: Panpan Li, Tianhong Xu, Peng Liu

Förderung

  • Natural Science Foundation of Shanghai

Zitieren

APA

Yang, Y., Li, J., Wang, W., Wang, Y., Maihemaiti, A., Ren, L., Lan, T., Zhou, C., Li, P., Wang, P., Aihemaiti, X., Chen, F., Xu, T., Xu, J., & Liu, P. (2023). The evolving diagnosis and treatment paradigms of multiple myeloma in China: 15 years' experience of 1256 patients in a national medical center. Cancer Medicine. https://doi.org/10.1002/cam4.5737

Vancouver

Yang Y, Li J, Wang W, Wang Y, Maihemaiti A, Ren L, et al. The evolving diagnosis and treatment paradigms of multiple myeloma in China: 15 years' experience of 1256 patients in a national medical center. Cancer Medicine. 2023. doi:10.1002/cam4.5737

BibTeX
@article{Yang2023,
  author = {Yang, Yang and Li, Jing and Wang, Wenjing and Wang, Yawen and Maihemaiti, Aziguli and Ren, Liang and Lan, Tianwei and Zhou, Chi and Li, Panpan and Wang, Pu and Aihemaiti, Xianmuseye and Chen, Feifei and Xu, Tianhong and Xu, Jiadai and Liu, Peng},
  title = {The evolving diagnosis and treatment paradigms of multiple myeloma in China: 15 years' experience of 1256 patients in a national medical center},
  journal = {Cancer Medicine},
  year = {2023},
  doi = {10.1002/cam4.5737}
}
Kostenlos starten →